Siobhan Glavey, Honorary Senior Lecturer at RCSI, Consultant Haematologist at Beaumont Hospital. Pic: Ray Lohan/RCSI (No Fee)
By combining genomic testing and next-generation sequencing technology, a new partnership led by RCSI researchers aims to advance predictive tests for multiple myeloma (MM), the second most common blood cancer in Ireland.
The study will be carried out at Beaumont Hospital Dublin and run through the Blood Cancer Network Ireland with several other cancer hospitals in Ireland participating. It represents a collaboration between RCSI University of Medicine and Health Sciences and SkylineDx with funding support from Amgen; Celgene, a Bristol Myers Squibb company; and Janssen.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
